

Overview of R&D Activities

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Lifecycle Management Marketing Unit Tatsuro Kosaka

July 31/August 1, 2008



Forward Looking Statements

This presentation may include forward looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.



Projects under Development (as of July 2008)

	Phase I	> Phase II	> Phase III	> Filed
Oncology	R1273 (BC)	<u>Actemra (multiple myeloma)</u> <i>Avastin (NSCLC) Avastin (BC) Tarceva (PC) R744 (Mircera CIA)</i>	Epogin (CIA) Avastin (Adj. CC)# Avastin (GC)# Avastin (Adj. BC)# Herceptin (GC)# Xeloda (GC)	Xeloda (CRC/ combo)
Bone & Joint		R484 (Bonviva oral osteoporosis)	R484 (Bonviva iv osteoporo ED-71(osteoporosis) <u>Actemra (sJIA)</u> R1594 (RA) #	sis) Actemra (RA)
Renal			R744 (Mircera renal anemia)	
Transplant, Immunology Infection	<u>Actemra (SLE)</u> <u>Actemra</u> (castleman's disease) NA808 (<i>chronic hepatitis C</i>)	Actemra (crohn's disease)	Pegasys / Copegus (live Pegasys (chronic hepatitis	•
Others	*GM-611 (diabetic gastroparesis) <i>R1583 (type II diabetes)</i> CSG452 <i>(type II diabetes)</i> <i>R1579 (type II diabetes)</i>	<u>*GM-611(IBS)</u> <u>*GM-611(diabetic_gastrop</u> <i>R1678 (schizophrenia) #</i>	paresis)	Epogin (autologous transfusion)

*GM-611 is being considered for out-licensing (*Italics: Roche projects*, <u>Underlined</u>: <u>overseas' clinical development</u>, #: participation in multi-national studies)



4


R&D Topics (April ~ July 2008)

May	R435 (Avastin)	:Joined multinational phase III study conducted by Roche for adjuvant breast cancer
■ May	ED-71	Entered into an agreement with Taisho Pharmaceutical Co., Ltd, to co-develop and co-market ED-71 for osteoporosis in Japan
■ May	R1678	Decided to join multinational phase II study conducted by Roche for schizophrenia
■ Jun	EPOCH(EPOGIN)	:Started additional phase III study for treatment of chemotherapy-induced anemia
■ Jun	R1579	:Started phase I study for type II diabetes
■ Jul	AVS	:Withdrew the application and suspended the development for subarachnoidal hemorrhage because the additional phase III study under review did not meet the endpoint
■ Jul	SG-75	Licensed-out the import and marketing rights to Merck Pharmaceutical (HK) Ltd. in China
■ Jul	MRA(Actemra)	:Obtained positive recommendation from FDA AdCom



Projected Submissions

Filings planned each year



Contacts:

Corporate Communications Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp Masayuki Yamada, Seiji Shimada, Hiroshi Araki

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm.co.jp

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita